Lacidofil, a branded blend of the probiotic strains L. rhamnosus Rosell-11 and L. helveticus Rosell-52 marketed by Lallemand, was associated with improved eradication rates of H. pylori, along with improved self-reported measures of health,in a population of 90 subjects. The findings of this study were published in Frontiers in Gastroenterology.
 
H. pylori infection is type of bacteria which infects the stomach or small intestine, and can damage the stomach lining and lead to complications if not treated with a course of antibiotics, such as chronic gastritis, peptic ulcer, lymphoma, and gastric cancer, according to the authors.
 
In the study, adults with H. pylori infection were administered either a placebo or the probiotic for a period of two weeks, alongside a standard triple therapy used for H. pylori infections. After this, the subjects continued with just the probiotic or placebo alone for an additional four weeks, to complete a six-week intervention period. 
 
Gastrointestinal comfort and quality of life criteria were assessed in all subjects at baseline, and at two and six weeks of treatment.
 
The analyses showed a statistically significant decrease in self-reported gastrointestinal discomfort and an increase in general health-related quality of life scores at week six compared to the placebo group.

Additionally, Lacidofil helped to increase the eradication rate of H. pylori in the volunteers.
 
“Backed by over 29 positive clinical trials with over 1,000 participants and pre-clinical scientific evidence, Lacidofil has consistently demonstrated its beneficial effects on maintaining a healthy intestinal microbiota, leading to overall well-being. This new study strengthens the evidence already available showing that Lacidofil is an effective adjuvant to standard therapy for H. pylori eradication and reduces the side effects of the antibiotics in this therapy,” said Marie-Laure Oula, clinical program manager at Lallemand Health Solutions.